Back Article

  • Atkinson AP, Cedzynski M, Szemraj J, Swierzko A, BakRomaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML, Kilpatrick DC, 2004: L-ficolin in children with recurrent respiratory infections[J]. Clin Exp Immunol, 138, 517-520. doi: 10.1111/cei.2004.138.issue-3

  • Chapman SJ, Vannberg FO, Khor CC, Segal S, Moore CE, Knox K, Day NP, Davies RJ, Crook DW, Hill AV, 2007: Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease[J]. Mol Immunol, 44, 3267-3270. doi: 10.1016/j.molimm.2006.04.013

  • Chen T, Hu Y, Ding Q, Yu J, Wang F, Luo F, Zhang XL, 2015: Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases[J]. Virol Sin, 30, 249-260. doi: 10.1007/s12250-015-3605-4

  • Dimitrov DS, 2000: Cell biology of virus entry[J]. Cell, 10, 697-702.

  • Endo Y, Sato Y, Matsushita M, Fujita T, 1996: Cloning and characterization of the human lectin P35 gene and its related gene[J]. Genomics, 36, 515-521. doi: 10.1006/geno.1996.0497

  • Ezekowitz RAB, Kuhlman M, Groopman JE, Byrn RA, 1989: A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus[J]. J Exp Med, 169, 185-196. doi: 10.1084/jem.169.1.185

  • Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO, 2006: Mannosebinding lectin and its genetic variants[J]. Genes Immun, 7, 85e94-.

  • Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ, 2003: Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal[J]. Stat Med, 22, 573-593. doi: 10.1002/sim.1342

  • Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, 2009: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model[J]. Lancet, 373, 48-57. doi: 10.1016/S0140-6736(08)61697-9

  • Haurum JS, Thiel S, Jones IM, Fische PB, Laursen SB, Jensenius JC, 1993: Complement activation upon binding of mannanbinding protein to HIV envelope glycoproteins[J]. Aids, 7, 1307-1313. doi: 10.1097/00002030-199310000-00002

  • Hoffmann JA, Kafatos FC, Janeway Jr. CA, Ezekowitz RAB, 1999: Phylogenetic perspectives in innate immunity[J]. Science, 284, 1313-1318. doi: 10.1126/science.284.5418.1313

  • Hummelshøj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P, 2007: Molecular organization of human Ficolin-2[J]. Mol Immunol, 44, 401-411. doi: 10.1016/j.molimm.2006.02.023

  • Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ, 2005: Restricted Variable Residues in the Cterminal Segment of HIV-1 V3 Loop Regulate the Molecular Anatomy of CCR5 Utilization[J]. J Mol Biol, 350, 699-712. doi: 10.1016/j.jmb.2005.05.024

  • Ichijo H, Ronnstrand L, Miyagawa K, Ohashi H, Heldin CH, Miyazono K, 1991: Purification of transforming growth factorbeta 1 binding proteins from porcine uterus membranes[J]. J Biol Chem, 266, 22459-22464.

  • Keeffe JR, Gnanapragasam PNP, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL, 2011: Designed oligomers of cyanovirin-N show enhanced HIV neutralization[J]. P Natl Acad Sci USA, 108, 14079-14084. doi: 10.1073/pnas.1108777108

  • Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE, Koch C, Matsushita M, Shiraki H, Stewart K, Tsujimura M, Turner ML, 2003: No strong relationship between mannan binding lectin or plasma ficolins and chemotherapyrelated infections[J]. Clin Exp Immunol, 134, 279-284. doi: 10.1046/j.1365-2249.2003.02284.x

  • Lars H, Tom E M, Thor U, Bjørn C, Pål A, Stig SF, 2003: Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy[J]. JAIDS, 32, 354-361.

  • Li GR, Liu J, Pan Q, Song ZB, Luo FL, Wang SR, Zhang XL, Zhou X, 2009: Synthesis and anti-HIV activity of [ddN]-[ddN] dimers and benzimidazole nucleoside dimers[J]. Chem Biodivers, 6, 2200-2207. doi: 10.1002/(ISSN)1612-1880

  • Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL, 2008: Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses[J]. J Virol, 82, 638-651. doi: 10.1128/JVI.01691-07

  • Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang XL, 2009: Specifically binding of Lficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation[J]. Cell Mol Immunol, 6, 235-244. doi: 10.1038/cmi.2009.32

  • Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T, 2005: Human M-ficolin is a secretory protein that activates the lectin complement pathway[J]. J Immunol, 175, 3150-3156. doi: 10.4049/jimmunol.175.5.3150

  • Lu J, Le Y, 1998: Ficolins and the fibrinogen-like domain[J]. Immunobiology, 199, 190-199. doi: 10.1016/S0171-2985(98)80026-0

  • Lu J, Le Y, Kon OL, Chan J, Lee SH, 1996: Biosynthesis of human ficolin, an Escherichia coli-binding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor[J]. Immunology, 89, 289-294. doi: 10.1046/j.1365-2567.1996.d01-732.x

  • Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T, 1996: A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin[J]. J Biol Chem, 271, 2448-2454. doi: 10.1074/jbc.271.5.2448

  • Pan Q, Chen H, Wang F, Jeza ViT, Hou W, Zhao Y, Xiang T, Zhu Y, EndoY , Fujita T, Zhang XL, 2012: L-ficolin binds to glycoproteins HA and NA and inhibits influenza A virus infection both in vitro and in vivo[J]. J Innate Immun, 4, 312-324. doi: 10.1159/000335670

  • Saarloos MN, Lint TF, Spear GT, 1995: Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells[J]. Clin Exp Immunol, 99, 189-195.

  • Sarma JV, Ward PA, 2011: The complement system[J]. Cell Tissue Res, 343, 227-235. doi: 10.1007/s00441-010-1034-0

  • Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N, 1998: Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family[J]. J Biol Chem, 273, 20721-20727. doi: 10.1074/jbc.273.33.20721

  • Trujillo JR, Rogers R, Molina R M, Dangond F, McLane MF, Essex M, Brain JD, 2007: Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor[J]. Proc Natl Acad Sci USA, 104, 5097-5102. doi: 10.1073/pnas.0611263104

  • Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V, 2009: Reduction of hepatitis C virus using Lectin affinity plasmapheresis in dialysis patients[J]. Blood Purificat, 27, 64-69.

  • Wyatt R, Sodroski J, 1998: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens[J]. Science, 280, 1884-1888. doi: 10.1126/science.280.5371.1884

  • Williams BG, Granich R, Dye C, 2011: Role of acute infection in HIV transmission[J]. Lancet, 378, 1913-. doi: 10.1016/S0140-6736(11)61832-1

  • Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT, 2004: Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization[J]. AIDS Res Hum Retroviruses, 20, 327-335. doi: 10.1089/088922204322996563

  • Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL, 2014: Ficolin-2 inhibits Hepatitis C Virus infection, whereas apolipoprotein E3 mediates viral immune escape[J]. J Immunol, 193, 783-796. doi: 10.4049/jimmunol.1302563

  • Zhang XL, Liu M, Xie P, Wan S, Yea JT, Zhou X, Wu J, 2004: Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells[J]. Bioorg Med Chem Lett, 14, 3789-3792. doi: 10.1016/j.bmcl.2004.04.092